Clinical trial · people
SS-31 (elamipretide) lowered blood HtrA2 after STEMI heart attack
Checked against the paper Clinical trialPublished by PepVault
The takeaway
In a small heart attack study, elamipretide was linked to lower levels of a blood marker the team proposes for mitochondria-driven heart cell death. It does not show effects on heart damage or recovery.
- Kind
- Clinical trial
- Studied in
- People
- Published
- 2019
- Journal
- Eur Heart J Acute Cardiovasc Care
What they tested
The team asked whether blood levels of HtrA2, a protein they propose as a marker of mitochondria-driven heart cell death, rise after a STEMI heart attack and whether elamipretide lowers them.
How the study was done
A small biomarker study within the phase 2a EMBRACE trial. It included 19 patients with a first-time acute anterior STEMI (a type of heart attack) after PCI, a procedure to open the blocked artery; 10 of them got elamipretide. It also included 16 healthy donors and a mouse model in which the left anterior descending heart artery was blocked.

What they found
In people with STEMI, median blood HtrA2 was 1805.5 pg/mL, against 392.4 pg/mL in healthy donors. Patients who got elamipretide had a median of 496.5 pg/mL, a significant drop compared with the 1805.5 pg/mL STEMI level. In mice, blocking the heart artery raised plasma HtrA2 from 117.4 fg/ml to 525.2 fg/ml.
What it doesn’t show
This was a very small substudy that measured a blood marker, not heart damage or patient outcomes, and HtrA2 is not yet an established marker. The team says the results must be confirmed in a larger clinical trial.
The paper
Hortmann et al. The mitochondria-targeting peptide elamipretide diminishes circulating HtrA2 in ST-segment elevation myocardial infarction. Eur Heart J Acute Cardiovasc Care. 2019.
The compound
More studies on SS-31
- SS-31 (elamipretide) eye drops missed main vision goal in LHON trialRandomized trial · people · 2024
- SS-31: wearable data grouped responders with 100% accuracyRandomized trial · people · 2023
- SS-31: no 12-week benefit, walk gains by 36 weeks open-labelRandomized trial · people · 2021
- SS-31 raised muscle ATP capacity after one dose in older adultsRandomized trial · people · 2021
- SS-31: walk distance rose with dose in 5-day MMPOWER trialRandomized trial · people · 2018
- SS-31: less kidney hypoxia after renal artery stenting in pilotRandomized trial · people · 2017
- Every study on SS-31
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.